Cerus Revenue
Biotechnology Research • 
Concord, California, United States • 201-500 Employees
Cerus revenue & valuation
| Annual revenue | $216,400,000 |
| Revenue per employee | $558,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $692,500,000 |
| Total funding | No funding |
Key Contacts at Cerus
Monique Ono
Executive Assistant to the Chief Executive Officer and Chief Financial Officer
Company overview
| Headquarters | 1220 Concord Ave, Suite 600, Concord, California 94520, US |
| Phone number | +19252886000 |
| Website | |
| NAICS | 541714 |
| SIC | 809 |
| Keywords | Healthcare, Transfusion Medicine, Patient Safety, Public Health, Plasma, Platelets, Blood Safety, Pathogen Inactivation, Hospital Safety, Pandemic Preparedness, Pathogen Reduction, Bleeding, Blood Supply |
| Founded | 1992 |
| Employees | 201-500 |
| Socials |
Cerus Email Formats
Cerus uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@cerus.com), used 72.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@cerus.com | 72.4% |
{first name}{last name} | johndoe@cerus.com | 22.6% |
{last name}{last name} | doedoe@cerus.com | 2.7% |
About Cerus
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Cerus has 178 employees across 15 departments.
Departments
Number of employees
Funding Data
Cerus has never raised funding before.
Cerus Tech Stack
Discover the technologies and tools that power Cerus's digital infrastructure, from frameworks to analytics platforms.
Video players
Mobile frameworks
JavaScript libraries
SEO
JavaScript libraries
Analytics
Programming languages
Tag managers
Blogs
Page builders
Analytics
Germany
Saudi Arabia
France
Australia
Netherlands
PeruFrequently asked questions
4.8
40,000 users
